A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Open-label, prospective, two part study evaluating IFN-γ 1b at a dose of 200μg by
subcutaneous injection every day either alone or in combination with Adefovir dipivoxil or
Adefovir dipivoxil alone at a dose of 10mg QD in patients with chronic Hepatitis B.